GET THE APP
The Swedish Association of the Pharmaceutical Industry AB (LIF) is a trade association for the research based pharmaceutical industry. LIF holds more than 60 pharmaceutical companies under its membership for developing and producing new medicines for the improvement of patient’s health and quality of life. It operates as a service organization for the member companies and continuously informs them for the developments influencing the work conditions for their operations in Sweden. LIF through its partnership with different levels of government, national agencies and key health care providers, support its members by enhancing the health care system, and fosters the development, access and correct utilization of innovative medicines and vaccines. The company is headquartered in Stockholm, Sweden.
The pharmaceutical business in Sweden yearly spends around 9 billion SEK on innovative work in Sweden. All out fares of pharmaceuticals from Sweden in 2015 were around 71 billion SEK, and the exchange surplus in pharmaceuticals in 2015 was around 37 billion. Our part organizations have around 11 500 representatives in Sweden.
The pharmaceutical business contributes more than 35 billion SEK every year to Sweden's GDP. The pharmaceutical business is the mechanical division which has the most astounding included quality per representative, more than four times higher than the normal for the entire economy. The pharmaceutical business and its suppliers utilize around 20,000 individuals around Sweden. Pharmaceutical fares represent 6 percent of aggregate Swedish fares. Sends out surpass imports by more than 37 billion, which relates to half of the Swedish exchange excess. The pharmaceutical business is each year putting almost 9 billion in R&D. 21 percent of the representatives of the Swedish pharmaceutical industry is working in R&D. No other industry has as high an extent of representatives with graduate studies. About one in five postgraduate degrees in business working in the pharmaceutical business. The exploration power of the pharmaceutical business is somewhere around six and ten times higher than in the economy on the loose.
New restorative medicines have diminished mortality significantly in various genuine sicknesses, for example, malignancy, heart assaults and HIV/AIDS. Future in Sweden is expanding by one year at regular intervals. 33% of this expansion is credited to new restorative medicines. Sweden's aggregate consumption for drugs has amid the previous decade expanded substantially more gradually than medicinal services costs as a rule. In the course of recent years, drug consumptions per capita really declined.Read More»